Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 to 75 years of age (inclusive) at the time of screening.~* Females of childbearing potential, defined as a female who is fertile following menarche, must have a negative serum pregnancy test at screening and agree to use an acceptable method of contraception throughout their participation in the study.~Note: Female subjects who have been surgically sterilized (e.g., hysterectomy or bilateral tubal ligation) or who are postmenopausal (defined as total cessation of menses for \> 1 year) will not be considered female subjects of childbearing potential.~* Subject is hospitalized with liver cirrhosis and/or OHE and has a confirmed diagnosis of OHE at Baseline.~* Subject has a Grade 2 or Grade 3 HE episode according to the HE Grading Instrument (HEGI) following 8 to 12 hours of intravenous (IV) hydration and lactulose treatment.~Exclusion Criteria:~* Subject has an uncontrolled major psychiatric disorder including major depression or psychoses as determined by the investigator.~* Subject has been diagnosed with an infection for which they are currently taking oral or parenteral antibiotics, which cannot be discontinued at time of enrollment. Note: Subjects currently taking Rifaximin are not excluded~* Subject shows presence of intestinal obstruction or has inflammatory bowel disease.~* Subject has uncontrolled Type 1 or Type 2 diabetes. Note: Subjects with controlled diabetes may be enrolled if they are on stable doses of oral hypoglycemic drugs for at least 3 months prior to screening, and demonstrate clinically acceptable blood glucose control at Baseline, as determined by the investigator.~* Subject has an active malignancy (exceptions: non-melanoma skin cancers).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 40 mg Rifaximin SSD once daily (Type: EXPERIMENTAL): 40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
- Cohort 2 40 mg Rifaximin SSD twice daily (Type: EXPERIMENTAL): 40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
- Cohort 3 80 mg Rifaximin SSD once daily (Type: EXPERIMENTAL): 80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
- Cohort 4 80 mg Rifaximin SSD twice daiy (Type: EXPERIMENTAL): 80 mg Rifaximin sustained extended release (SER) rifaximin SSD twice daily (BID) and lactulose
- Cohort 5 Placebo twice daily (Type: EXPERIMENTAL): SSD placebo twice daily (BID) and lactulose

Based on this trial design, predict the completion outcome and termination type (if applicable).